Resumen de Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine

Jordi Remón Masip, F. Tabbò, Begoña Jiménez, Ana Collazo Lorduy, Javier de Castro Carpeño, S. Novello

• Next-generation ALK TKIs have become the new standard of care in first-line setting in advanced ALK-positive NSCLC patients. However, sequential strategies at progression are relevant, as may have an impact on patients’ outcome. In this commentary we discuss whether genomic-tailored strategies at progression would be more suitable for improving outcome of ALK-positive NSCLC patients.